Neuronal Ceroid Lipofuscinosis (CLN5-Related)

Neuronal Ceroid Lipofuscinoses (NCLs), also known as Batten disease, are a group of inherited neurodegenerative disorders characterized by the accumulation of lipopigments (lipofuscin) in the body's tissues, particularly in the brain. CLN5-related NCL was originally identified in Finland but has since been found worldwide. It is also known as Finnish variant late infantile NCL.

CLN5 disease typically presents between ages 4 and 7 years with motor clumsiness, attention problems, and difficulties with learning. Progressive visual impairment leads to blindness, usually within a few years of symptom onset. Seizures develop in most affected children and can be difficult to control. The condition is progressive and fatal.

As the disease progresses, children lose previously acquired motor and cognitive skills. They develop movement disorders including ataxia (poor coordination) and spasticity. Speech is lost, and affected individuals eventually become unable to walk or communicate. Life expectancy is typically into the teens or early twenties, though this varies.

CLN5-related NCL is caused by mutations in the CLN5 gene, which encodes a lysosomal protein of uncertain function. The condition is inherited in an autosomal recessive pattern. Diagnosis is confirmed by genetic testing, enzyme activity assays, and finding characteristic storage material in tissues. Research into gene therapy and enzyme replacement therapy is ongoing.

NutraHacker examines the following gene related to CLN5-Related Neuronal Ceroid Lipofuscinosis:

• CLN5

For more information about your own genetic profile as related to Neuronal Ceroid Lipofuscinosis, please check out our NutraHacker Carrier Status and Drug Response Report.

Or to get going without any further delay, upload raw DNA data and find out more about your carrier status today.